Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roluperidone for negative symptoms of schizophrenia
NCT03397134Phase 3Completed
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Dec 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of roluperidone in schizophrenia, sponsored by Minerva Neurosciences, Inc.. Started Dec 2017; status: completed.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03397134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03397134.